记能达 （多奈单抗）纳入首版商保创新药目录

Core Viewpoint - The announcement by China's National Healthcare Security Administration on December 7 includes the new basic medical insurance drug catalog and the first version of the commercial insurance innovative drug catalog, highlighting the inclusion of Eli Lilly's Alzheimer's disease modification therapy, Donanemab, in the commercial insurance innovative drug catalog [1] Group 1 - The new drug catalog fills three significant gaps in traditional treatments for Alzheimer's disease: the absence of targeted Aβ plaque drugs, the lack of disease-modifying therapies for Alzheimer's, and the unavailability of drugs targeting mild cognitive impairment due to Alzheimer's [1]